Aldosterone Antagonist
PreclinicalSmall molecule
Aldosterone Antagonist is one of 29 small molecule programs targeting Hypertension. It is currently in Preclinical.
2
Indications
2
Total Trials
0
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
566 competitors in Hypertension
#DrugCompanyPhaseTrials
1Apresoline
NovartisPreclinical
Zebeta
TevaPreclinical
Edarbi
TakedaPreclinical
Aceon
Institut de Recherches Internationales ServierPreclinical
Winrevair
Merck & Co.Preclinical
Deltavit
HHyundai Pharmaceutical Co., LTD.
Preclinical
Disalcid
JJoslin Diabetes Center
Preclinical
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Cecon
MMcGuff Pharmaceuticals, Inc.
Preclinical
Avastin
BBio-Thera Solutions
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Aldosterone Antagonist. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- IImperial College London